The global bioactive wound management market size was valued USD 1401.8 million in 2020 and expected to reach at USD 2910.36 million by 2027, witnessing a CAGR rate of 11% during the forecast period 2021-2027. Wound is a disruption of skin epithelial lining or mucosa which results in thermal or physical damage. Depending upon healing nature and duration, wound is classified as chronic wounds and acute wounds. Wounds can be caused due to incisions made in the body during surgeries. In bioactive wound management a sterile dressing or pad is applied on the wounds to assist healing and to prevent further contamination and injuries. In bioactive wound management dress in different from normal bandage and designed specially to stay in direct contact with wound. Bioactive wound management market is in nascent stage. Many innovative products are being developed and designed by market players in order to provide quick healing for the chronic wounds like venous leg ulcers, diabetic foot ulcers. For example, Tegaderm Alginate silver dressing by 3M Company is an antibacterial silver dressing for wounds which provide moisture to the wounds because of soft gelling absorbency, so as to heal quickly. Bioactive wound products are useful during severe trauma, diabetic ulcers, and burns. Introduction of Dermagraft and Alpigraph have provided major support for the bioactive wound management market growth. Major players are focused on collaborations and partnerships, product launches and investments on R&D activities. For instance, in 2015 3M Healthcare acquired Ivera Medical Corporation and in the same year Smith & Nephew acquired DeOST LLC and DeLLC, a part of DeOST group.